Aminoacyl-tRNA synthetases as drug targets in eukaryotic parasites

International Journal for Parasitology: Drugs and Drug Resistance

Volumn 4, Issue 1, 2014, Pages 1-13

  Pham, James S ^a   Dawson, Karen L ^a   Jackson, Katherine E ^a   Lim, Erin E ^a   Pasaje, Charisse Flerida A ^a   Turner, Kelsey E C ^a   Ralph, Stuart A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Aminoacyl tRNA synthetase; Drug target; Parasite; Protein translation

Indexed keywords

EID: 84896936059     PISSN: 22113207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpddr.2013.10.001     Document Type: Review

References (118)

1. Ahel I., Korencic D., Ibba M., Söll D. Trans-editing of mischarged tRNAs. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:15422-15427.
2. Ali V., Nozaki T. Current therapeutics, their problems, and sulfur-containing-amino-acid metabolism as a novel target against infections by "amitochondriate" protozoan parasites. Clin. Microbiol. Rev. 2007, 20:164-187.
3. Alfonzo J.D., Blanc V., Estevez A.M., Rubio M.A., Simpson L. C to U editing of the anticodon of imported mitochondrial tRNA(Trp) allows decoding of the UGA stop codon in Leishmania tarentolae. EMBO J. 1999, 18:7056-7062.
4. Antonellis A., Green E.D. The role of aminoacyl-tRNA synthetases in genetic diseases. Annu. Rev. Genom. Human Genet. 2008, 9:87-107.
5. Arakaki T.L., Carter M., Napuli A.J., Verlinde C.L.M.J., Fan E., Zucker F., Buckner F.S., Van Voorhis W.C., Hol W.G.J., Merritt E.A. The structure of tryptophanyl-tRNA synthetase from Giardia lamblia reveals divergence from eukaryotic homologs. J. Struct. Biol. 2010, 171:238-243.
6. Azcarate I.G., Marin-Garcia P., Camacho N., Perez-Benavente S., Puyet A., Diez A., Ribas de Pouplana L., Bautista J.M. Insights into the preclinical treatment of blood-stage malaria by the antibiotic borrelidin. Br. J. Pharmacol. 2013, 169:645-658.
7. Baird J.K. Effectiveness of antimalarial drugs. N. Engl. J. Med. 2005, 352:1565-1577.
8. Bandi C., Trees A.J., Brattig N.W. Wolbachia in filarial nematodes: evolutionary aspects and implications for the pathogenesis and treatment of filarial diseases. Vet. Parasitol. 2001, 98:215-238.
9. Barrett M.P., Boykin D.W., Brun R., Tidwell R.R. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br. J. Pharmacol. 2007, 152:1155-1171.
10. Berge J.M., Copley R.C., Eggleston D.S., Hamprecht D.W., Jarvest R.L., Mensah L.M., O'Hanlon P.J., Pope A.J. Inhibitors of bacterial tyrosyl tRNA synthetase: synthesis of four stereoisomeric analogues of the natural product SB-219383. Bioorg. Med. Chem. Lett. 2000, 10:1811-1814.
11. Bhatt T.K., Khan S., Dwivedi V.P., Banday M.M., Sharma A., Chandele A., Camacho N., de Pouplana L.R., Wu Y., Craig A.G., Mikkonen A.T., Maier A.G., Yogavel M. Malaria parasite tyrosyl-tRNA synthetase secretion triggers pro-inflammatory responses. Nat. Commun. 2011, 2:530.
12. Bour T., Akaddar A., Lorber B., Blais S., Balg C., Candolfi E., Frugier M. Plasmodial aspartyl-tRNA synthetases and peculiarities in Plasmodium falciparum. J. Biol. Chem. 2009, 284:18893-18903.
13. Brown M.J., Carter P.S., Fenwick A.S., Fosberry A.P., Hamprecht D.W., Hibbs M.J., Jarvest R.L., Mensah L., Milner P.H., O'Hanlon P.J., Pope A.J., Richardson C.M., West A., Witty D.R. The antimicrobial natural product chuangxinmycin and some synthetic analogues are potent and selective inhibitors of bacterial tryptophanyl tRNA synthetase. Bioorg. Med. Chem. Lett. 2002, 12:3171-3174.
14. Bunjun S., Stathopoulos C., Graham D., Min B., Kitabatake M., Wang A.L., Wang C.C., Vivares C.P., Weiss L.M., Soll D. A dual-specificity aminoacyl-tRNA synthetase in the deep-rooted eukaryote Giardia lamblia. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:12997-13002.
15. Burrows J.N., Burlot E., Campo B., Cherbuin S., Jeanneret S., Leroy D., Spangenberg T., Waterson D., Wells T.N., Willis P. Antimalarial drug discovery - the path towards eradication. Parasitology 2013, 1-12.
16. Casewell M.W., Hill R.L. Mupirocin ('pseudomonic acid')-a promising new topical antimicrobial agent. J. Antimicrob. Chemother. 1987, 19:1-5.
17. Cestari I., Stuart K. Inhibition of isoleucyl-tRNA synthetase as a potential treatment for human African trypanosomiasis. J. Biol. Chem. 2013, 288:14256-14263.
18. Charriere F., Helgadottir S., Horn E.K., Soll D., Schneider A. Dual targeting of a single tRNA(Trp) requires two different tryptophanyl-tRNA synthetases in Trypanosoma brucei. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:6847-6852.
19. Crepin T., Peterson F., Haertlein M., Jensen D., Wang C., Cusack S., Kron M. A hybrid structural model of the complete Brugia malayi cytoplasmic asparaginyl-tRNA synthetase. J. Mol. Biol. 2011, 405:1056-1069.
20. Critchley I.A., Young C.L., Stone K.C., Ochsner U.A., Guiles J., Tarasow T., Janjic N. Antibacterial activity of REP8839, a new antibiotic for topical use. Antimicrob. Agents Chemother. 2005, 49:4247-4252.
21. Critchley I.A., Green L.S., Young C.L., Bullard J.M., Evans R.J., Price M., Jarvis T.C., Guiles J.W., Janjic N., Ochsner U.A. Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections. J. Antimicrob. Chemother. 2009, 63:954-963.
22. Croft S.L., Olliaro P. Leishmaniasis chemotherapy-challenges and opportunities. Clin. Microbiol. Infect. 2011, 17:1478-1483.
23. Danel F., Caspers P., Nuoffer C., Hartlein M., Kron M.A., Page M.G. Asparaginyl-tRNA synthetase pre-transfer editing assay. Curr. Drug Disc. Technol. 2011, 8:66-75.
24. de Jonge M.J., Dumez H., Verweij J., Yarkoni S., Snyder D., Lacombe D., Marreaud S., Yamaguchi T., Punt C.J., van Oosterom A. Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours. Eur. J. Cancer 2006, 42:1768-1774.
25. Derbyshire E.R., Mazitschek R., Clardy J. Characterization of Plasmodium liver stage inhibition by halofuginone. ChemMedChem 2012, 7:844-849.
26. Ding D., Meng Q., Gao G., Zhao Y., Wang Q., Nare B., Jacobs R., Rock F., Alley M.R., Plattner J.J., Chen G., Li D., Zhou H. Design, synthesis, and structure-activity relationship of Trypanosoma brucei leucyl-tRNA synthetase inhibitors as antitrypanosomal agents. J. Med. Chem. 2011, 54:1276-1287.
27. Elkin M., Ariel I., Miao H.Q., Nagler A., Pines M., de-Groot N., Hochberg A., Vlodavsky I. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res. 1999, 59:4111-4118.
28. Fevre E.M., Wissmann B.V., Welburn S.C., Lutumba P. The burden of human African trypanosomiasis. PLoS Negl. Trop. Dis. 2008, 2:e333.
29. Folz S.D., Lee B.L., Nowakowski L.H., Conder G.A. Anticoccidial evaluation of halofuginone, lasalocid, maduramicin, monensin and salinomycin. Vet. Parasitol. 1988, 28:1-9.
30. Fukunaga R., Yokoyama S. Aminoacylation complex structures of leucyl-tRNA synthetase and tRNALeu reveal two modes of discriminator-base recognition. Nat. Struct. Mol. Biol. 2005, 12:915-922.
31. Gao Y.M., Wang X.J., Zhang J., Li M., Liu C.X., An J., Jiang L., Xiang W.S. Borrelidin, a potent antifungal agent: insight into the antifungal mechanism against Phytophthora sojae. J. Agric. Food Chem. 2012, 60:9874-9881.
32. Geerts S., Gryseels B. Drug resistance in human helminths: current situation and lessons from livestock. Clin. Microbiol. Rev. 2000, 13:207-222.
33. Gething P.W., Patil A.P., Smith D.L., Guerra C.A., Elyazar I.R., Johnston G.L., Tatem A.J., Hay S.I. A new world malaria map: plasmodium falciparum endemicity in 2010. Malar. J. 2011, 10:378.
34. Gowri V.S., Ghosh I., Sharma A., Madhubala R. Unusual domain architecture of aminoacyl tRNA synthetases and their paralogs from Leishmania major. BMC Genom. 2012, 13:621.
35. Green L.S., Bullard J.M., Ribble W., Dean F., Ayers D.F., Ochsner U.A., Janjic N., Jarvis T.C. Inhibition of methionyl-tRNA synthetase by REP8839 and effects of resistance mutations on enzyme activity. Antimicrob. Agents Chemother. 2009, 53:86-94.
36. Greenwood R.C., Gentry D.R. Confirmation of the antibacterial mode of action of SB-219383, a novel tyrosyl tRNA synthetase inhibitor from a Micromonospora sp. J. Antibiot. (Tokyo) 2002, 55:423-426.
37. Guo M., Chong Y.E., Beebe K., Shapiro R., Yang X.L., Schimmel P. The C-Ala domain brings together editing and aminoacylation functions on one tRNA. Science 2009, 325:744-747.
38. Guo M., Schimmel P. Essential nontranslational functions of tRNA synthetases. Nat. Chem. Biol. 2013, 9:145-153.
39. Hasenoehrl A., Galic T., Ergovic G., Marsic N., Skerlev M., Mittendorf J., Geschke U., Schmidt A., Schoenfeld W. In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans. Antimicrob. Agents Chemother. 2006, 50:3011-3018.
40. Hoen R., Novoa E.M., Lopez A., Camacho N., Cubells L., Vieira P., Santos M., Marin-Garcia P., Bautista J.M., Cortes A., Ribas de Pouplana L., Royo M. Selective inhibition of an apicoplastic aminoacyl-tRNA synthetase from Plasmodium falciparum. ChemBioChem 2013, 14:499-509.
41. Hoepfner D., McNamara C.W., Lim C.S., Studer C., Riedl R., Aust T., McCormack S.L., Plouffe D.M., Meister S., Schuierer S., Plikat U., Hartmann N., Staedtler F., Cotesta S., Schmitt E.K., Petersen F., Supek F., Glynne R.J., Tallarico J.A., Porter J.A., Fishman M.C., Bodenreider C., Diagana T.T., Movva N.R., Winzeler E.A. Selective and specific inhibition of the Plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. Cell Host Microbe 2012, 11:654-663.
42. Ibba M., Soll D. Aminoacyl-tRNA synthesis. Annu. Rev. Biochem. 2000, 69:617-650.
43. Ishiyama A., Iwatsuki M., Namatame M., Nishihara-Tsukashima A., Sunazuka T., Takahashi Y., Omura S., Otoguro K. Borrelidin, a potent antimalarial: stage-specific inhibition profile of synchronized cultures of Plasmodium falciparum. J. Antibiot. (Tokyo) 2011, 64:381-384.
44. Istvan E.S., Dharia N.V., Bopp S.E., Gluzman I., Winzeler E.A., Goldberg D.E. Validation of isoleucine utilization targets in Plasmodium falciparum. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:1627-1632.
45. Jackson K.E., Habib S., Frugier M., Hoen R., Khan S., Pham J.S., Ribas de Pouplana L., Royo M., Santos M.A., Sharma A., Ralph S.A. Protein translation in Plasmodium parasites. Trends Parasitol. 2011, 27:467-476.
46. Jackson K.E., Pham J.S., Kwek M., De Silva N.S., Allen S.M., Goodman C.D., McFadden G.I., Ribas de Pouplana L., Ralph S.A. Dual targeting of aminoacyl-tRNA synthetases to the apicoplast and cytosol in Plasmodium falciparum. Int. J. Parasitol. 2012, 42:177-186.
47. Jarvest R.L., Berge J.M., Houge-Frydrych C.S., Janson C., Mensah L.M., O'Hanlon P.J., Pope A., Saldanha A., Qiu X. Interaction of tyrosyl aryl dipeptides with S. aureus tyrosyl tRNA synthetase: inhibition and crystal structure of a complex. Bioorg. Med. Chem. Lett. 1999, 9:2859-2862.
48. Jarvest R.L., Berge J.M., Berry V., Boyd H.F., Brown M.J., Elder J.S., Forrest A.K., Fosberry A.P., Gentry D.R., Hibbs M.J., Jaworski D.D., O'Hanlon P.J., Pope A.J., Rittenhouse S., Sheppard R.J., Slater-Radosti C., Worby A. Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens. J. Med. Chem. 2002, 45:1959-1962.
49. Jarvest R.L., Berge J.M., Brown M.J., Brown P., Elder J.S., Forrest A.K., Houge-Frydrych C.S., O'Hanlon P.J., McNair D.J., Rittenhouse S., Sheppard R.J. Optimisation of aryl substitution leading to potent methionyl tRNA synthetase inhibitors with excellent gram-positive antibacterial activity. Bioorg. Med. Chem. Lett. 2003, 13:665-668.
50. Kanamaru T., Nakano Y., Toyoda Y., Miyagawa K.I., Tada M., Kaisho T., Nakao M. In vitro and in vivo antibacterial activities of TAK-083, an agent for treatment of Helicobacter pylori infection. Antimicrob. Agents Chemother. 2001, 45:2455-2459.
51. Kawamura T., Liu D., Towle M.J., Kageyama R., Tsukahara N., Wakabayashi T., Littlefield B.A. Anti-angiogenesis effects of borrelidin are mediated through distinct pathways: threonyl-tRNA synthetase and caspases are independently involved in suppression of proliferation and induction of apoptosis in endothelial cells. J. Antibiot. (Tokyo) 2003, 56:709-715.
52. Keller T.L., Zocco D., Sundrud M.S., Hendrick M., Edenius M., Yum J., Kim Y.J., Lee H.K., Cortese J.F., Wirth D.F., Dignam J.D., Rao A., Yeo C.Y., Mazitschek R., Whitman M. Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat. Chem. Biol. 2012, 8:311-317.
53. Khan S., Sharma A., Jamwal A., Sharma V., Pole A.K., Thakur K.K. Uneven spread of cis- and trans-editing aminoacyl-tRNA synthetase domains within translational compartments of P. falciparum. Sci. Rep. 2011, 1:188.
54. Khan S., Garg A., Camacho N., Van Rooyen J., Kumar Pole A., Belrhali H., Ribas de Pouplana L., Sharma V., Sharma A. Structural analysis of malaria-parasite lysyl-tRNA synthetase provides a platform for drug development. Acta Crystallogr. D Biol. Crystallogr. 2013, 69:785-795.
55. Khan S., Garg A., Sharma A., Camacho N., Picchioni D., Saint-Leger A., Ribas de Pouplana L., Yogavel M. An appended domain results in an unusual architecture for malaria parasite tryptophanyl-tRNA synthetase. PLoS One 2013, 8:e66224.
56. Kim S., Lee S.W., Choi E.-C., Choi S.Y. Aminoacyl-tRNA synthetases and their inhibitors as a novel family of antibiotics. Appl. Microbiol. Biotechnol. 2003, 61:278-288.
57. Kobayashi S., Ueno M., Suzuki R., Ishitani H., Kim H.S., Wataya Y. Catalytic asymmetric synthesis of antimalarial alkaloids febrifugine and isofebrifugine and their biological activity. J. Org. Chem. 1999, 64:6833-6841.
58. Koh C.Y., Kim J.E., Shibata S., Ranade R.M., Yu M., Liu J., Gillespie J.R., Buckner F.S., Verlinde C.L., Fan E., Hol W.G. Distinct states of methionyl-tRNA synthetase indicate inhibitor binding by conformational selection 2012, Structure.
59. Koh C.Y., Kim J.E., Napoli A.J., Verlinde C.L., Fan E., Buckner F.S., Van Voorhis W.C., Hol W.G. Crystal structures of Plasmodium falciparum cytosolic tryptophanyl-tRNA synthetase and its potential as a target for structure-guided drug design. Mol. Biochem. Parasitol. 2013, 189:26-32.
60. Koon H.B., Fingleton B., Lee J.Y., Geyer J.T., Cesarman E., Parise R.A., Egorin M.J., Dezube B.J., Aboulafia D., Krown S.E. Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma. J. Acquir. Immune Defic. Syndr. 2011, 56:64-68.
61. Kron M., Marquard K., Hartlein M., Price S., Leberman R. An immunodominant antigen of Brugia malayi is an asparaginyl-tRNA synthetase. FEBS Lett. 1995, 374:122-124.
62. Kron M., Petridis M., Milev Y., Leykam J., Hartlein M. Expression, localization and alternative function of cytoplasmic asparaginyl-tRNA synthetase in Brugia malayi. Mol. Biochem. Parasitol. 2003, 129:33-39.
63. Kron M.A., Wang C., Vodanovic-Jankovic S., Howard O.M., Kuhn L.A. Interleukin-8-like activity in a filarial asparaginyl-tRNA synthetase. Mol. Biochem. Parasitol. 2012, 185:66-69.
64. Kron M.A., Metwali A., Vodanovic-Jankovic S., Elliott D. Nematode asparaginyl-tRNA synthetase resolves intestinal inflammation in mice with T-cell transfer colitis. Clin. Vaccine Immunol. 2013, 20:276-281.
65. Larson E.T., Kim J.E., Castaneda L.J., Napuli A.J., Zhang Z., Fan E., Zucker F.H., Verlinde C.L., Buckner F.S., Van Voorhis W.C., Hol W.G., Merritt E.A. The double-length tyrosyl-tRNA synthetase from the eukaryote Leishmania major forms an intrinsically asymmetric pseudo-dimer. J. Mol. Biol. 2011, 409:159-176.
66. Larson E.T., Kim J.E., Zucker F.H., Kelley A., Mueller N., Napuli A.J., Verlinde C.L., Fan E., Buckner F.S., Van Voorhis W.C., Merritt E.A., Hol W.G. Structure of Leishmania major methionyl-tRNA synthetase in complex with intermediate products methionyladenylate and pyrophosphate. Biochimie 2011, 93:570-582.
67. Lee J.W., Beebe K., Nangle L.A., Jang J., Longo-Guess C.M., Cook S.A., Davisson M.T., Sundberg J.P., Schimmel P., Ackerman S.L. Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration. Nature 2006, 443:50-55.
68. Lee S.W., Cho B.H., Park S.G., Kim S. Aminoacyl-tRNA synthetase complexes: beyond translation. J. Cell Sci. 2004, 117:3725-3734.
69. Leung C.C., Rieder H.L., Lange C., Yew W.W. Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur. Respir. J. 2011, 37:690-711.
70. Liu J., Istvan E.S., Gluzman I.Y., Gross J., Goldberg D.E. Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:8840-8845.
71. Lustigman S., Prichard R.K., Gazzinelli A., Grant W.N., Boatin B.A., McCarthy J.S., Basanez M.-G. A research agenda for helminth diseases of humans: the problem of helminthiases. PLoS Negl. Trop. Dis. 2012, e1582.
72. Lv P.C., Zhu H.L. Aminoacyl-tRNA synthetase inhibitors as potent antibacterials. Curr. Med. Chem. 2012, 19:3550-3563.
73. Merritt E.A., Arakaki T.L., Gillespie R., Napuli A.J., Kim J.E., Buckner F.S., Van Voorhis W.C., Verlinde C.L., Fan E., Zucker F., Hol W.G. Crystal structures of three protozoan homologs of tryptophanyl-tRNA synthetase. Mol. Biochem. Parasitol. 2011, 177:20-28.
74. Nacher M. Helminth-infected patients with malaria: a low profile transmission hub?. Malar. J. 2012, 11:376.
75. Nakama T., Nureki O., Yokoyama S. Structural basis for the recognition of isoleucyl-adenylate and an antibiotic, mupirocin, by isoleucyl-tRNA synthetase. J. Biol. Chem. 2001, 276:47387-47393.
76. Nass G., Hasenbank R. Effect of Borrelidin on the threonyl-tRNA-synthetase activity and the regulation of threonine-biosynthetic enzymes in Saccharomyces cerivisiae. Mol. Gen. Genet. 1970, 108:28-32.
77. Niemann M., Schneider A., Cristodero M. Mitochondrial translation in trypanosomatids: a novel target for chemotherapy?. Trends Parasitol. 2011, 27:429-433.
78. Ochsner U.A., Sun X., Jarvis T., Critchley I., Janjic N. Aminoacyl-tRNA synthetases: essential and still promising targets for new anti-infective agents. Exp. Opin. Invest. Drugs 2007, 16:573-593.
79. Otoguro K., Ui H., Ishiyama A., Kobayashi M., Togashi H., Takahashi Y., Masuma R., Tanaka H., Tomoda H., Yamada H., Omura S. In vitro and in vivo antimalarial activities of a non-glycosidic 18-membered macrolide antibiotic, borrelidin, against drug-resistant strains of Plasmodia. J. Antibiot. (Tokyo) 2003, 56:727-729.
80. Patel J.B., Gorwitz R.J., Jernigan J.A. Mupirocin resistance. Clin. Infect. Dis 2009, 49:935-941.
81. Prichard R.K., Basanez M.-G., Boatin B.A., McCarthy J.S., Garcia H.H., Yang G.-J., Sripa B., Lustigman S. A research agenda for helminth diseases of humans: intervention for control and elimination. PLoS Negl. Trop. Dis. 2012, 6:e1549.
82. Ramirez B.L., Howard O.M., Dong H.F., Edamatsu T., Gao P., Hartlein M., Kron M. Brugia malayi asparaginyl-transfer RNA synthetase induces chemotaxis of human leukocytes and activates G-protein-coupled receptors CXCR1 and CXCR2. J. Infect. Dis. 2006, 193:1164-1171.
83. Ranade R.M., Gillespie J.R., Shibata S., Verlinde C.L.M.J., Fan E., Hol W.G.J., Buckner F.S. Induced resistance to methionyl-tRNA synthetase inhibitors in Trypanosoma brucei. Is due to overexpression of the target?. Antimicrob. Agents Chemother. 2013, 57:3021-3028.
84. Rao K.V. PA 155A: a new antibiotic. Antibiot. Chemother. 1960, 10:312-315.
85. Rateb M.E., Yu Z., Yan Y., Yang D., Huang T., Vodanovic-Jankovic S., Kron M.A., Shen B. Medium optimization of Streptomyces sp. 17944 for tirandamycin B production and isolation and structural elucidation of tirandamycins H, I and J. J. Antibiot. (Tokyo) 2013.
86. Rock F.L., Mao W., Yaremchuk A., Tukalo M., Crepin T., Zhou H., Zhang Y.K., Hernandez V., Akama T., Baker S.J., Plattner J.J., Shapiro L., Martinis S.A., Benkovic S.J., Cusack S., Alley M.R. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 2007, 316:1759-1761.
87. Rodriguez J.B., Szajnman S.H. New antibacterials for the treatment of toxoplasmosis; a patent review. Expert. Opin. Ther. Pat. 2012, 22:311-333.
88. Rossignol J.F. Cryptosporidium and Giardia: treatment options and prospects for new drugs. Exp. Parasitol. 2010, 124:45-53.
89. Rottenberg M.E., Masocha W., Ferella M., Petitto-Assis F., Goto H., Kristensson K., McCaffrey R., Wigzell H. Treatment of African trypanosomiasis with cordycepin and adenosine deaminase inhibitors in a mouse model. J. Infect. Dis. 2005, 192:1658-1665.
90. Ruan B., Bovee M.L., Sacher M., Stathopoulos C., Poralla K., Francklyn C.S., Söll D. A unique hydrophobic cluster near the active site contributes to differences in borrelidin inhibition among threonyl-tRNA synthetases. J. Biol. Chem. 2005, 280:571-577.
91. Schneider A. Unique aspects of mitochondrial biogenesis in trypanosomatids. Int. J. Parasitol. 2001, 31:1403-1415.
92. Seiradake E., Mao W., Hernandez V., Baker S.J., Plattner J.J., Alley M.R., Cusack S. Crystal structures of the human and fungal cytosolic Leucyl-tRNA synthetase editing domains: a structural basis for the rational design of antifungal benzoxaboroles. J. Mol. Biol. 2009, 390:196-207.
93. Shibata S., Gillespie J.R., Kelley A.M., Napuli A.J., Zhang Z., Kovzun K.V., Pefley R.M., Lam J., Zucker F., Van Voorhis W.C., Merritt E.A., Hol W.G.J., Verlinde C.L.M.J., Fan E., Buckner F.S. Selective inhibitors of methionyl-tRNA synthetase have potent activity on Trypanosoma brucei infection in mice. Antimicrob. Agents Chemother. 2011, 55:1982-1989.
94. Shibata S., Gillespie J.R., Ranade R.M., Koh C.Y., Kim J.E., Laydbak J.U., Zucker F.H., Hol W.G., Verlinde C.L., Buckner F.S., Fan E. Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization. J. Med. Chem. 2012, 55:6342-6351.
95. Smirnova E.V., Lakunina V.A., Tarassov I., Krasheninnikov I.A., Kamenski P.A. Noncanonical functions of aminoacyl-tRNA synthetases. Biochemistry (Mosc) 2012, 77:15-25.
96. Sokabe M., Okada A., Yao M., Nakashima T., Tanaka I. Molecular basis of alanine discrimination in editing site. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:11669-11674.
97. Sokabe M., Ose T., Nakamura A., Tokunaga K., Nureki O., Yao M., Tanaka I. The structure of alanyl-tRNA synthetase with editing domain. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:11028-11033.
98. Stefanska A.L., Coates N.J., Mensah L.M., Pope A.J., Ready S.J., Warr S.R. SB-219383, a novel tyrosyl tRNA synthetase inhibitor from a Micromonospora sp. I. Fermentation, isolation and properties. J. Antibiot. (Tokyo) 2000, 53:345-350.
99. Stuart K., Brun R., Croft S., Fairlamb A., Gurtler R.E., McKerrow J., Reed S., Tarleton R. Kinetoplastids: related protozoan pathogens, different diseases. J. Clin. Invest. 2008, 118:1301-1310.
100. Sugawara A., Tanaka T., Hirose T., Ishiyama A., Iwatsuki M., Takahashi Y., Otoguro K., Omura S., Sunazuka T. Borrelidin analogues with antimalarial activity: design, synthesis and biological evaluation against Plasmodium falciparum parasites. Bioorg. Med. Chem. Lett. 2013, 23:2302-2305.
101. Sukuru S.C., Crepin T., Milev Y., Marsh L.C., Hill J.B., Anderson R.J., Morris J.C., Rohatgi A., O'Mahony G., Grotli M., Danel F., Page M.G., Hartlein M., Cusack S., Kron M.A., Kuhn L.A. Discovering new classes of Brugia malayi asparaginyl-tRNA synthetase inhibitors and relating specificity to conformational change. J. Comput. Aided Mol. Des. 2006, 20:159-178.
102. Tan M., Wang M., Zhou X.L., Yan W., Eriani G., Wang E.D. The Yin and Yang of tRNA: proper binding of acceptor end determines the catalytic balance of editing and aminoacylation. Nucleic Acids Res. 2013, 41:5513-5523.
103. Tsuchiya E., Yukawa M., Miyakawa T., Kimura K.I., Takahashi H. Borrelidin inhibits a cyclin-dependent kinase (CDK), Cdc28/Cln2, of Saccharomyces cerevisiae. J. Antibiot. (Tokyo) 2001, 54:84-90.
104. Upcroft P., Upcroft J.A. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin. Microbiol. Rev. 2001, 14:150-164.
105. Vondenhoff G.H., Van Aerschot A. Aminoacyl-tRNA synthetase inhibitors as potential antibiotics. Eur. J. Med. Chem. 2011, 46:5227-5236.
106. Wang X.D., Deng R.C., Dong J.J., Peng Z.Y., Gao X.M., Li S.T., Lin W.Q., Lu C.L., Xiao Z.P., Zhu H.L. 3-Aryl-4-acyloxyethoxyfuran-2(5H)-ones as inhibitors of tyrosyl-tRNA synthetase: synthesis, molecular docking and antibacterial evaluation. Bioorg. Med. Chem. 2013, 21:4914-4922.
107. Wilkinson B., Gregory M.A., Moss S.J., Carletti I., Sheridan R.M., Kaja A., Ward M., Olano C., Mendez C., Salas J.A., Leadlay P.F., vanGinckel R., Zhang M.Q. Separation of anti-angiogenic and cytotoxic activities of borrelidin by modification at the C17 side chain. Bioorg. Med. Chem. Lett. 2006, 16:5814-5817.
108. Wilson R.J. Progress with parasite plastids. J. Mol. Biol. 2002, 319:257-274.
109. Xiao Z.P., He X.B., Peng Z.Y., Xiong T.J., Peng J., Chen L.H., Zhu H.L. Synthesis, structure, molecular docking, and structure-activity relationship analysis of enamines: 3-aryl-4-alkylaminofuran-2(5H)-ones as potential antibacterials. Bioorg. Med. Chem. 2011, 19:1571-1579.
110. Xiao Z.P., Ma T.W., Liao M.L., Feng Y.T., Peng X.C., Li J.L., Li Z.P., Wu Y., Luo Q., Deng Y., Liang X., Zhu H.L. Tyrosyl-tRNA synthetase inhibitors as antibacterial agents: synthesis, molecular docking and structure-activity relationship analysis of 3-aryl-4-arylaminofuran-2(5H)-ones. Eur. J. Med. Chem. 2011, 46:4904-4914.
111. Yu Z., Vodanovic-Jankovic S., Ledeboer N., Huang S.X., Rajski S.R., Kron M., Shen B. Tirandamycins from Streptomyces sp. 17944 inhibiting the parasite Brugia malayi asparagine tRNA synthetase. Org. Lett. 2011, 13:2034-2037.
112. Yu Z., Vodanovic-Jankovic S., Kron M., Shen B. New WS9326A congeners from Streptomyces sp. 9078 inhibiting Brugia malayi asparaginyl-tRNA synthetase. Org. Lett. 2012, 14:4946-4949.
113. Zhang C.M., Christian T., Newberry K.J., Perona J.J., Hou Y.M. Zinc-mediated amino acid discrimination in cysteinyl-tRNA synthetase. Journal of molecular biology 2003, 327:911-917.
114. Zhang F., Du J., Wang Q., Hu Q., Zhang J., Ding D., Zhao Y., Yang F., Wang E., Zhou H. Discovery of N-(4-sulfamoylphenyl)thioureas as Trypanosoma brucei leucyl-tRNA synthetase inhibitors. Org. Biomol. Chem. 2013, 11:5310-5324.
115. Zhao Y., Wang Q., Meng Q., Ding D., Yang H., Gao G., Li D., Zhu W., Zhou H. Identification of Trypanosoma brucei leucyl-tRNA synthetase inhibitors by pharmacophore- and docking-based virtual screening and synthesis. Bioorg. Med. Chem. 2012, 20:1240-1250.
116. Zhou H., Sun L., Yang X.L., Schimmel P. ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase. Nature 2013, 494:121-124.
117. Zhu S., Wang J., Chandrashekar G., Smith E., Liu X., Zhang Y. Synthesis and evaluation of 4-quinazolinone compounds as potential antimalarial agents. Eur. J. Med. Chem. 2010, 45:3864-3869.
118. Zhu S., Chandrashekar G., Meng L., Robinson K., Chatterji D. Febrifugine analogue compounds: synthesis and antimalarial evaluation. Bioorg. Med. Chem. 2012, 20:927-932.